Abstract
Cytosine arabinoside (ara-C) and gemcitabine (dFdC) are two standard chemotherapy drugs used in the treatment of patients with various cancers. To alter the pharmacokinetic and pharmacodynamic properties of these molecules, we conjugated a synthetic phospholipid to both ara-C and dFdC and investigated their chemotherapeutic potential. The dFdC conjugate had greater cytotoxic activity compared with the ara-C conjugate and demonstrated notable cytotoxicity against all human cell lines tested.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology*
-
Buffers
-
Cell Line
-
Cytarabine / analogs & derivatives*
-
Cytarabine / pharmacology
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / chemistry*
-
Deoxycytidine / pharmacology
-
Gemcitabine
-
Humans
-
Inhibitory Concentration 50
-
Phosphatidic Acids / chemical synthesis
-
Phosphatidic Acids / chemistry*
-
Phosphatidic Acids / pharmacokinetics
-
Phosphatidic Acids / pharmacology*
-
Ribonucleotide Reductases / antagonists & inhibitors
-
Solubility
Substances
-
Antineoplastic Agents
-
Buffers
-
Phosphatidic Acids
-
Cytarabine
-
Deoxycytidine
-
Ribonucleotide Reductases
-
Gemcitabine